+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Protease Inhibitors Market, By Mechanism of Action, By Application, By End-Use, By Region; Trend Analysis, Competitive Market Share & Forecast, 2020-2026

  • ID: 5235713
  • Report
  • December 2020
  • Region: Global
  • 180 pages
  • Blueweave Consulting & Research Pvt Ltd

FEATURED COMPANIES

  • AbbVie Inc.
  • BioCryst Pharmaceuticals
  • Centogene AG
  • CSL Behring LLC.
  • CYTOSKELETON INC.
  • Genentech Inc.
  • MORE
Protease Inhibitors Market worth USD Mn in 2019

According to the author, the global protease inhibitors market has reached USD Million in 2019 and is further projected to reach USD Million by 2026, growing at a CAGR during the forecast period. The increasing prevalence of viral diseases such as HIV/AIDS and hepatitis C is expected to drive the market during the forecast period. The rising awareness about anti-retroviral therapy and cancer treatment is another major factor contributing to the growth of the global protease inhibitors market. Extensive research and development activities in the field of protein purification, pharmacology, animal tissue culture, and molecular biology are expected to drive the global market by 2026.

Rising awareness about anti-retroviral therapy and cancer treatment

The global protease inhibitors market is expected to expand at a significant pace during the forecast period. The development of pharmaceutical protease inhibitors is of great interest which targets the specific protease enzyme (for example, in HIV anti-retroviral drugs). Thus, the increasing prevalence of viral diseases such as HIV/AIDS and hepatitis C is expected to drive the market during the forecast period. The rising awareness about anti-retroviral therapy and cancer treatment is another major factor contributing to the growth of the global protease inhibitors market. Extensive research and development activities in the field of protein purification, pharmacology, animal tissue culture, and molecular biology are expected to drive the global market by 2026.

Increasing cases of HIV infected people to boost market growth for protease inhibitor market

According to WHO, around 37.9 million people were living with HIV (including 1.7 million children), with a global HIV prevalence of 0.8% among adults in 2018 and this number is rising every year. With the rise in the number of infected people coupled with rising awareness among people about HIV, the demand for drugs for its treatment is also increasing which may boost the market growth. The increasing number of HIV cases globally coupled with the high prevalence of this disease along with the increasing number of tests for HIV diagnosis is expected to drive the market growth for the protease inhibitor market.

Time-consuming approval process of drugs to restrain the market growth

From the time of research and development to the official launch of drugs, it takes a very long time. Even after development and successful trials, approval from regulatory authority takes a lot of time and a lot of entrepreneurs and big players do not invest in drug manufacturing due to this reason. So, the launching of the drug takes a lot of time which is declining the protease inhibitor market growth. Over the forecast period, this may hamper the growth of injectable drugs for the type 2 diabetes market.

Serine protease inhibitors segment occupy the major share of the global protease inhibitors market

The serine protease inhibitor segment leads to the protease inhibitors market. It is anticipated to drive the growth for antiretroviral drugs in the protease inhibitors market on the back of its effectiveness in the treatment. Serine protease inhibitor forms a proteolytically inactive stoichiometric complex with the Serpins proteases which will play a vital role in the regulation of blood coagulation, complement activation, generation of kinins, and fibrinolysis. Thus, owing to its huge effectiveness in the therapy the protease inhibitors market will grow at a higher rate during the forecasting period.

Global protease inhibitors market: Regional insights

Factors such as the high prevalence of HIV and chronic HCV in the region, the growing industrial sector, and advanced health care infrastructure are anticipated to drive the market in North America during the forecast period. Furthermore, to strengthen their position in an established market, prominent players are focusing on the region. The market in the Asia Pacific is expected to register the maximum growth rate during the forecast period, due to factors such as rising health care expenditure, increasing geriatric population, surging disposable income, high prevalence of chronic diseases, growing focus of global pharmaceutical companies on the Asia Pacific, and increasing research activities. Furthermore, a rise in awareness about anti-retroviral therapy in regions are driving the global protease inhibitors market.

The leading players in the global protease inhibitors market include Thermo Fisher Scientific Inc., Sigma-Aldrich, Inc., CYTOSKELETON, INC., Merck & Co., Inc., Genentech, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, GlaxoSmithKline plc, Vertex Pharmaceuticals, CSL Behring LLC., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., KalVista Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Inc., Centogene AG & Other prominent players. key players in the protease inhibitors market are engaged in mergers and acquisitions, extensive R&D activities, the launch of cost-effective and efficient vaccine products, and collaborative partnerships.

Don’t miss the business opportunity of the Protease Inhibitors market. Consult our analyst, gain crucial insights, and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of global Protease Inhibitors market size & forecast. The report promises to provide recent technology trends of Protease Inhibitors market and industry insights which help decision-makers to make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • BioCryst Pharmaceuticals
  • Centogene AG
  • CSL Behring LLC.
  • CYTOSKELETON INC.
  • Genentech Inc.
  • MORE
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Region
2.5. Assumption & Limitation

3. Executive Summary

4. Global Protease Inhibitors Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Recent Development
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Intensity of Rivalry
4.5. Impact of Covid-19 on Protease Inhibitors Industry

5. Global Protease Inhibitors Market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Mechanism of action
5.2.1.1. Serine protease inhibitors
5.2.1.2. Cysteine protease inhibitors
5.2.1.3. Amino peptidase inhibitor
5.2.1.4. Aspartic protease inhibitors
5.2.1.5. Metalloprotease inhibitors
5.2.1.6. Others
5.2.2. By Application
5.2.2.1. Commodity protease inhibitor
5.2.2.2. Research tool protease inhibitor
5.2.2.3. Protease inhibitor drugs
5.2.2.4. Others
5.2.3. By End-User
5.2.3.1. Hospitals & diagnostic centers
5.2.3.2. Pharmaceutical industries
5.2.3.3. Academic
5.2.3.4. Research institutes
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. Asia Pacific
5.2.4.4. Latin America
5.2.4.5. Middle East & Africa

6. North America Protease Inhibitors Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Mechanism of action
6.2.2. By Application
6.2.3. By End-User
6.2.4. By Country
6.2.4.1. United States
6.2.4.2. Canada

7. Europe Protease Inhibitors Market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Mechanism of action
7.2.2. By Application
7.2.3. By End-User
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. Italy
7.2.4.3. France
7.2.4.4. United Kingdom
7.2.4.5. Spain
7.2.4.6. Rest of Europe

8. Asia Pacific Protease Inhibitors Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Mechanism of action
8.2.2. By Application
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Rest of Asia Pacific

9. Latin America Protease Inhibitors Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Mechanism of action
9.2.2. By Application
9.2.3. By End-User
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Mexico
9.2.4.3. Rest of Latin America

10. Middle East & Africa Protease Inhibitors Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Mechanism of action
10.2.2. By Application
10.2.3. By End-User
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. Egypt
10.2.4.3. Qatar
10.2.4.4. UAE
10.2.4.5. GCC
10.2.4.6. Rest of Middle East & Africa

11. Competitive Landscape
11.1. List of Key Players and Their Offerings
11.2. Market/Ranking Share Analysis
11.3. Competitive Benchmarking, By Operating Parameters

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
12.1. Thermo Fisher Scientific Inc.
12.2. Sigma-Aldrich, Inc.
12.3. CYTOSKELETON, INC.
12.4. Merck & Co., Inc.
12.5. Genentech, Inc.
12.6. Boehringer Ingelheim International GmbH
12.7. AbbVie Inc.
12.8. Bristol-Myers Squibb Company
12.9. Janssen Pharmaceutical Companies
12.10. GlaxoSmithKline plc
12.11. Vertex Pharmaceuticals
12.12. CSL Behring LLC.
12.13. Takeda Pharmaceutical Company Limited
12.14. Pharming Technologies B.V.
12.15. KalVista Pharmaceuticals, Inc
12.16. BioCryst Pharmaceuticals
12.17. Ionis Pharmaceuticals, Inc.
12.18. Centogene AG
12.19. Other prominent players
Note: Product cover images may vary from those shown
  • Thermo Fisher Scientific Inc.
  • Sigma-Aldrich Inc.
  • CYTOSKELETON INC.
  • Merck & Co. Inc.
  • Genentech Inc.
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceutical Companies
  • GlaxoSmithKline plc
  • Vertex Pharmaceuticals
  • CSL Behring LLC.
  • Takeda Pharmaceutical Company Limited
  • Pharming Technologies B.V.
  • KalVista Pharmaceuticals Inc.
  • BioCryst Pharmaceuticals
  • Ionis Pharmaceuticals Inc.
  • Centogene AG
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll